Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.

Chen J, Reheman A, Gushiken FC, Nolasco L, Fu X, Moake JL, Ni H, López JA.

J Clin Invest. 2011 Feb;121(2):593-603. doi: 10.1172/JCI41062. Epub 2011 Jan 25.

PMID:
21266777
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Thrombotic thrombocytopenic purpura: reducing the risk?

Berndt MC, Andrews RK.

J Clin Invest. 2011 Feb;121(2):522-4. doi: 10.1172/JCI46091. Epub 2011 Jan 25.

PMID:
21266772
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Enhanced platelet adhesion and aggregation by endothelial cell-derived unusually large multimers of von Willebrand factor.

Kumar RA, Moake JL, Nolasco L, Bergeron AL, Sun C, Dong JF, McIntire LV.

Biorheology. 2006;43(5):681-91.

PMID:
17047284
[PubMed - indexed for MEDLINE]
4.

Recent advances in thrombotic thrombocytopenic purpura.

Sadler JE, Moake JL, Miyata T, George JN.

Hematology Am Soc Hematol Educ Program. 2004:407-23. Review.

PMID:
15561695
[PubMed - indexed for MEDLINE]
Free Article
5.

Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor.

Zhou Z, Dong JF.

Curr Vasc Pharmacol. 2012 Nov;10(6):762-6. Review.

PMID:
22022775
[PubMed - indexed for MEDLINE]
6.

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, López JA.

Blood. 2002 Dec 1;100(12):4033-9. Epub 2002 Jul 25.

PMID:
12393397
[PubMed - indexed for MEDLINE]
Free Article
7.

Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.

Tersteeg C, de Maat S, De Meyer SF, Smeets MW, Barendrecht AD, Roest M, Pasterkamp G, Fijnheer R, Vanhoorelbeke K, de Groot PG, Maas C.

Circulation. 2014 Mar 25;129(12):1320-31. doi: 10.1161/CIRCULATIONAHA.113.006727. Epub 2014 Jan 21.

PMID:
24449821
[PubMed - indexed for MEDLINE]
8.

Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Moake JL, McPherson PD.

Am J Med. 1989 Sep;87(3N):9N-15N.

PMID:
2486537
[PubMed - indexed for MEDLINE]
9.

Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission.

Lotta LA, Lombardi R, Mariani M, Lancellotti S, De Cristofaro R, Hollestelle MJ, Canciani MT, Mannucci PM, Peyvandi F.

J Thromb Haemost. 2011 Sep;9(9):1744-51. doi: 10.1111/j.1538-7836.2011.04428.x.

PMID:
21726405
[PubMed - indexed for MEDLINE]
10.

Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.

Rayes J, Hollestelle MJ, Legendre P, Marx I, de Groot PG, Christophe OD, Lenting PJ, Denis CV.

Blood. 2010 Jun 10;115(23):4870-7. doi: 10.1182/blood-2009-11-254193. Epub 2010 Mar 3.

PMID:
20200350
[PubMed - indexed for MEDLINE]
Free Article
12.

Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy.

Chung MC, Popova TG, Jorgensen SC, Dong L, Chandhoke V, Bailey CL, Popov SG.

J Biol Chem. 2008 Apr 11;283(15):9531-42. doi: 10.1074/jbc.M705871200. Epub 2008 Feb 8.

PMID:
18263586
[PubMed - indexed for MEDLINE]
Free Article
13.

Thrombotic thrombocytopenic purpura: understanding a disease no longer rare.

Moake JL, Chow TW.

Am J Med Sci. 1998 Aug;316(2):105-19. Review.

PMID:
9704664
[PubMed - indexed for MEDLINE]
14.

Generation and breakdown of soluble ultralarge von Willebrand factor multimers.

Turner N, Nolasco L, Moake J.

Semin Thromb Hemost. 2012 Feb;38(1):38-46. doi: 10.1055/s-0031-1300950. Epub 2012 Feb 7. Review.

PMID:
22314602
[PubMed - indexed for MEDLINE]
15.

Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.

Pruss CM, Golder M, Bryant A, Hegadorn C, Haberichter S, Lillicrap D.

J Thromb Haemost. 2012 May;10(5):940-50. doi: 10.1111/j.1538-7836.2012.04675.x.

PMID:
22372972
[PubMed - indexed for MEDLINE]
16.

Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.

Morioka Y, Casari C, Wohner N, Cho S, Kurata S, Kitano A, Christophe OD, Lenting PJ, Li R, Denis CV, Prévost N.

Blood. 2014 May 22;123(21):3344-53. doi: 10.1182/blood-2013-10-531392. Epub 2014 Apr 8.

PMID:
24713928
[PubMed - indexed for MEDLINE]
17.

Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.

Bao J, Xiao J, Mao Y, Zheng XL.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):397-407. doi: 10.1161/ATVBAHA.113.302547. Epub 2013 Dec 19.

PMID:
24357063
[PubMed - indexed for MEDLINE]
18.

von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.

Moake JL.

Semin Hematol. 2004 Jan;41(1):4-14. Review.

PMID:
14727254
[PubMed - indexed for MEDLINE]
19.

Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.

Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A.

J Lab Clin Med. 2001 Jan;137(1):70-6.

PMID:
11150026
[PubMed - indexed for MEDLINE]
20.

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.

Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, Scheiflinger F, Schwarz HP, Muchitsch EM.

Blood. 2012 Jun 21;119(25):6128-35. doi: 10.1182/blood-2011-09-380535. Epub 2012 Apr 23.

PMID:
22529289
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk